The company is set to open a therapeutic health and training center in Kelowna, British
Columbia in May of 2021
VANCOUVER, BC, Dec. 10, 2020 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (DTC: MCURF) (“Mind Cure” or the “Company”) is pleased today to announce its plans to open the first Mind Cure Health Center, which will offer psychedelic-assisted mental health therapy to patients as well as training to therapists. Located in Kelowna, British Columbia, the center is scheduled to open in May of 2021, and will offer patients access to therapeutic treatments with ketamine and psilocybin through utilizing Section 56 Exemptions, a legal exemption to Canadian drug laws granted by Health Canada.
“We have always seen our business as caring for individual mental health and wellness on a spectrum, from those who are suffering and are in need of relief to those who are looking for enhanced clarity, focus and overall well-being,” said Mind Cure President and CEO Kelsey Ramsden.
Mind Cure’s first Health Center will enable treatment and study of psychedelic-assisted therapy with personalized and technology enabled care, supporting individuals before, during and after treatment. The Kelowna location will offer eight treatment rooms and will serve a very important role to Mind Cure beyond its therapeutic opportunities. “This first Mind Cure Health Center will also act as a training hub as we advance our training model for therapists who want to offer psychedelic-assisted therapy in their clinics, or who want to better understand the care offered by Mind Cure so that they can feel confident referring patients,” continued Ramsden.
Mind Cure believes that a number of people seeking psychedelic-assisted therapy are not just those seeking relief from depression, migraines, and physical and psychological pain, but also individuals following the lead of executives, first from Silicon Valley and now, around the world, who have been looking to enhance their holistic wellness plans and productivity utilizing these therapeutic experiences. “Kelowna is a logical first location for a Mind Cure Health Center, both because of its proximity to Vancouver and Calgary, International Airports, as well as its growing local population and reputation as a destination city,” said Ramsden.
Mind Cure announced earlier this week that it is initiating its translational research program, focused on psilocybin, ketamine and ibogaine. The first two psychoactive compounds, psilocybin and ketamine, will be the first offered at the Health Center. Mind Cure also plans on rolling out an experience driven by technology for both therapists and patients, to enhance treatment potential and improve post-therapy integration and patient outcomes.
The Company has granted a total of 200,000 stock options to certain employees pursuant to the terms of the Company’s incentive stock option plan (the “Plan”). The stock options are exercisable at a price of $0.65 and subject to the terms of the Plan.
About Mind Cure Health Inc.
Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.
Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.
On Behalf of the Board of Directors
Philip Tapley, Chairman
Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mind Cure opening its first Health Center in Kelowna, BC; Mind Cure receiving a Section 56 Exemption from Health Canada; Mind Cure offering treatments starting with ketamine and psilocybin, Mind Cure enabling the treatment and study of psychedelic-assisted therapy; Mind Cure’s Health Center acting as a training hub for therapists.
Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian and global economy and Mind Cure’s business, and the extent and duration of such impact; Mind Cure being able to open its Health Center; Mind Cure receiving a Section 56 Exemption from Health Canada; that people are seeking psychedelic-assisted therapy for both mental health as well as holistic wellness reasons. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian and global economy, Mind Cure’s industry and its business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect its investments, results of operations, financial condition and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; Mind Cure not being able to open its Health Center; and Mind Cure not receiving a Section 56 Exemption from Health Canada. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com.
The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.
United States Advisory
The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:http://www.prnewswire.com/news-releases/mind-cure-moves-into-psychedelic-assisted-therapy-with-british-columbia-location-offering-ketamine-and-psilocybin-therapy-301189952.html
SOURCE Mind Cure Health Inc.